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Abstract
Background and Objective The extrapolation of estimated hazard functions can be an important part of cost-efectiveness 
analyses. Given limited follow-up time in the sample data, it may be expected that the uncertainty in estimates of hazards 
increases the further into the future they are extrapolated. The objective of this study was to illustrate how the choice of para-
metric survival model impacts on estimates of uncertainty about extrapolated hazard functions and lifetime mean survival.
Methods We examined seven commonly used parametric survival models and described analytical expressions and approxi-
mation methods (delta and multivariate normal) for estimating uncertainty. We illustrate the multivariate normal method 
using case studies based on four representative hypothetical datasets relecting hazard functions commonly encountered 
in clinical practice (constant, increasing, decreasing, or unimodal), along with a hypothetical cost-efectiveness analysis.
Results Depending on the survival model chosen, the uncertainty in extrapolated hazard functions could be constant, 
increasing or decreasing over time for the case studies. Estimates of uncertainty in mean survival showed a large variation 
(up to sevenfold) for each case study. The magnitude of uncertainty in estimates of cost efectiveness, as measured using the 
incremental cost per quality-adjusted life-year gained, varied threefold across plausible models. Diferences in estimates of 
uncertainty were observed even when models provided near-identical point estimates.
Conclusions Survival model choice can have a signiicant impact on estimates of uncertainty of extrapolated hazard functions, 
mean survival and cost efectiveness, even when point estimates were similar. We provide good practice recommendations 
for analysts and decision makers, emphasizing the importance of considering the plausibility of estimates of uncertainty in 
the extrapolated period as a complementary part of the model selection process.
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article (https ://doi.org/10.1007/s4027 3-019-00853 -x) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Estimates of lifetime mean survival are often a key compo-
nent of cost-efectiveness analyses, as they typically quantify 
the beneits of new treatments. Cost-efectiveness analyses 
play an important role in reimbursement decisions [1]. 
Clinical trials typically have a shorter follow-up period then 
the time horizon required in a cost-efectiveness analysis. 
Hence, extrapolation of hazard functions is often required 
to estimate lifetime mean survival. This may be achieved 
by itting commonly applied parametric survival models (as 
described in Sect. 2.1) to sample data. The National Insti-
tute for Health and Care Excellence Decision Support Unit 
Technical Support Document 14 describes diferent para-
metric survival models and suggestions for how to choose 
between them, highlighting the importance of considering 
uncertainty [2].
Extrapolation introduces additional uncertainty that does 
not occur for within-sample prediction. This is due to the 
absence of data to calibrate model estimates or validate 
their plausibility. For example, an exponential distribu-
tion may provide an adequate it to the observed data. By 
deinition, the suitability of the exponential model for the 
extrapolated period cannot be assessed from the observed 
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Key Points for Decision Makers 
Guidance is available on choosing between parametric 
survival models used in a cost-efectiveness analysis. 
However, this does not consider the impact of model 
choice on uncertainty in extrapolated hazard functions 
and lifetime mean survival. Intuitively, we might expect 
that this uncertainty increases the further into the future 
we extrapolate.
We illustrate, using seven commonly applied paramet-
ric survival models and four hypothetical datasets, that 
the choice of survival model can have a marked impact 
on resulting estimates of uncertainty about the hazard 
function, lifetime mean survival and cost efectiveness. 
Estimates of uncertainty about extrapolated hazard func-
tions could increase, decrease or be constant depending 
on the model used.
We provide recommendations on how the clinical plausi-
bility of estimates of uncertainty about hazard functions 
and estimates of cost efectiveness should be used as part 
of the model selection process.
methods (delta and multivariate normal approach) for when 
exact analytical solutions are not tractable. We then create 
four representative hypothetical datasets, relecting hazard 
functions commonly encountered in clinical practice for use 
in case studies, to illustrate the impact of model choice on 
estimates of uncertainty. We used one of these datasets to 
perform a hypothetical cost-efectiveness analysis. Section 3 
presents the results of the case studies and the cost-efective-
ness analysis. In Sect. 4, we provide recommendations on 
how to use the impact of survival model choice on estimates 
of uncertainty as part of the model selection process. We 
focus on extrapolating a single arm of a trial.
2  Methods
2.1  Commonly Applied Parametric Survival Models
For this study, we considered seven commonly applied par-
ametric survival models: exponential, Weibull, Gompertz, 
gamma, log-logistic, log-normal and generalised gamma dis-
tributions. With the exception of the Gompertz distribution, 
these models all belong to the generalised F family of distri-
butions [5, 6]. We originally also considered the generalised 
F model, but do not include it here, as the model estimation 
procedure did not always converge under the default settings 
[see Appendix 2 of the Electronic Supplementary Material 
(ESM) for more details]. The diferent survival models make 
diferent assumptions about their underlying hazard func-
tions over time: an exponential distribution assumes a con-
stant hazard; Weibull, Gompertz and gamma distributions 
allow for monotonically increasing or decreasing hazards 
over time; log-normal and log-logistic distributions allow 
the hazard function to be unimodal (also monotonically 
decreasing for the log-logistic) [6]. The generalised gamma 
distribution is the most lexible of the commonly applied 
models. It can model hazards that are constant, monotonic 
(increasing or decreasing), bathtub or arc shaped [7].
Table 1 describes the characteristics of seven commonly 
used survival models, including the survival function S(t) , 
hazard function h(t) and cumulative hazard function H(t) . 
These three functions are all related via the equation:
We focus on the hazard function because it provides 
insights into the natural history of a disease along with any 
time-varying responses to treatment [8]. We also consider 
the survival function because this is a clinically important 
statistic.
(1)H(t) = ∫
t
0
h(u)du = − ln (S(t)).
data. External evidence, such as clinical opinion, may be 
used to support the plausibility of extrapolated estimates. 
However, even if the exponential distribution is deemed suit-
able, there remains uncertainty that the model parameter 
estimated from the observed data will be the same in the 
future. Hence, there is extrapolation uncertainty in both the 
suitability of the chosen model and the suitability of the 
estimated parameters. As such, there is often an expecta-
tion amongst analysts and decision makers that uncertainty 
about estimates of hazard functions (as quantiied by their 
variance) should increase over the extrapolation period. The 
efect of this extrapolation uncertainty is recognised in the 
time-series literature, with extrapolations being associated 
with greater uncertainty than within-sample estimates [3, 
4]. To our knowledge, there has been little consideration of 
whether the use of commonly applied parametric survival 
models adequately relects extrapolation uncertainty.
Our study had two aims. The irst was to illustrate the 
impact of model choice on estimates of uncertainty about 
extrapolated hazard functions, estimates of lifetime mean 
survival and estimates of cost efectiveness. The second 
aim was to raise awareness of this impact when producing 
and critiquing survival models. We begin Sect. 2 by show-
ing how to derive estimates of uncertainty of extrapolated 
hazard functions and the estimated lifetime mean sur-
vival using both analytical expressions and approximation 
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2.2  Estimating Uncertainty About Hazard 
and Survival Estimates
In this section, we describe how to quantify the uncertainty 
in the hazard and survival functions and uncertainty in esti-
mates such as mean survival time. For illustration, we take 
a frequentist perspective and estimate parameters using 
maximum likelihood. Ideally, exact analytic expressions 
of variance would be available for the estimates of interest 
(hazard and survival functions, and mean survival time). 
However, as these are estimates of non-linear functions of 
model parameters, approximation methods are required.
Exact analytical expressions are available for the exponen-
tial model. The maximum likelihood estimate of the model 
parameter 휆 is:
(2)휆̂ =
∑
훿
i
∑
t
i
=
N
e
∑
t
i
,
where the subscript i denotes an individual, 훿
i
= 1 for an 
event and zero otherwise, t
i
 represents the observed times 
and N
e
 represents the number of events. As described in 
Collet [6], the variance of the estimated hazard function is 
the variance of the estimated model parameter 휆̂, given by:
From Eq. 3, the variance of the hazard function is constant 
with respect to time, which means that the uncertainty does 
not ‘fan out’ over time. Thus, for the exponential model, 
uncertainty about the hazard function depends only upon the 
sample data that are used to estimate 휆 and does not depend 
on whether we are considering the observed or unobserved 
period.
Estimates of uncertainty about the exponential survival 
function can be derived from the hazard function by using 
(3)Var
�
ĥ(t)
�
= Var
�
휆̂
�
=
∑
훿
i�∑
t
i
�2 =
�
휆̂
�2
N
e
.
Table 1  Overview of seven commonly used survival models and their characteristics (t ≥ 0)
훷 is the cumulative standard normal distribution; 훤 (t; 휆) = ∫ t
0
x
휆−1e−xdx
훤 (휆)
 , and e denotes the exponential function. Allowing � < 0 for the Gompertz 
implies that the survival function will never equal 0
Model (parameters) Survival function S(t) Cumulative hazard 
function H(t)
Hazard function h(t) Possible shapes 
of the hazard 
function
Exponential � > 0 e(−휆t) 휆t 휆 Constant
Weibull � > 0, � > 0 e(−휆t훾 ) 휆t훾 휆훾t훾−1 Constant
Increasing 
monotonically
Decreasing 
monotonically
Lognormal 휇 ∈ (−∞,∞), 
� > 0
1 −훷
(
log t−휇
휎
)
− ln
(
1 −훷
(
log (t)−휇
휎
))
1
휎
√
2휋
t
−1e
�
−
(log t−휇)2
2휎2
�
∕S(t) Increasing then 
decreasing
Log-logistic� > 0, � > 0 1
1+(훼t)훽 − ln
(
1
1+(훼t)
훽
)
훼훽(훼t)
훽−1
1+(훼t)훽
Decreasing 
monotonically
Increasing then 
decreasing
Gamma � > 0, � > 0 1 − 훤
[
휆−2e−훽 t; 휆−2
]
− ln (S(t)) 훽휆 t휆−1e−훽t
훤 (휆)S(t)
Constant
Increasing 
monotonically
Decreasing 
monotonically
Generalised gamma 
� ∈ (−∞,∞), � > 0, � > 0
⎧⎪⎨⎪⎩
1 − �
�
�−2
�
e−� t
� �
� ; �−2
�
if � > 0
�
�
�−2
�
e−� t
� �
� ; �−2
�
if � < 0
− ln (S(t)) |휆|
휎t훤 (휆−2)
훼휆
−2
e
−훼∕S(t),
where 훼 = 휆−2
(
e
−훽
t
)휆∕휎
Constant
Increasing 
monotonically
Decreasing 
monotonically
Bathtub
Arc-shaped
Gompertz 
� > 0, � ∈ (−∞,∞)
e
{
−
휆
휃
(
e
휃t
− 1
)} 휆
휃
(
e
휃t
− 1
)
휆e
휃t Constant
Increasing 
monotonically
Decreasing 
monotonically
 B. Kearns et al.
the relationship in Eq. 1. For the exponential model, the 
estimate of mean survival 휇̂  is given by:
A conidence interval for the estimated mean survival 
may be derived via the delta method:
Exact analytical expressions of variance (for hazard 
and survival functions) are not available for the other six 
commonly used parametric survival models. Two diferent 
approximation methods are commonly used to estimate vari-
ances of a function: the delta method [9] and the multivariate 
normal method [10].
The delta method estimates the variance of a function 
based on a linear approximation of the function [6]. The 
delta method may be used whenever the derivative of a func-
tion can be calculated. This includes all of the commonly 
used parametric survival functions in Table 1. To illustrate 
its use, we use the delta method to estimate the variance of 
the hazard function for both the exponential and Weibull 
models in Appendix 1 of the ESM. For the exponential 
model, applying the delta method gives the same equation 
for variance in the hazard as Eq. 3.
The multivariate normal method assumes that the esti-
mated model parameters 휃̂  follow a multivariate normal 
distribution: N
(
휃̂, Var
[
휃̂
])
 , where Var
(
휃̂
)
 is estimated dur-
ing model itting. For example, 휃̂ =
(
휆̂, 훾̂
)
 for the Weibull 
model, and Var
(
휃̂
)
 is the estimated variance-covariance 
matrix. Parameter samples are drawn from the normal dis-
tribution and used to generate sample estimates of both the 
hazard and survival functions using the formulas in Table 1. 
Variances and conidence intervals are then derived from 
these sample estimates. The multivariate normal method has 
been shown to provide similar estimates of uncertainty to 
the delta method [10]. Its main advantage over the delta 
method is that it is easier to implement as it avoids calculat-
ing derivatives.
The multivariate normal approximation is a Monte Carlo 
simulation-based method. If B Monte Carlo parameter sam-
ples are drawn from N
(
휃̂, Var
[
휃̂
])
 , with a single sample 
denoted as 휃
b
 ( b = 1,… , B ), then the variance of a function 
of the parameters, Var(g(휃)) , is approximated as:
(4)휇̂ =
1
휆̂
=
∑
t
i
N
e
.
(5)
Var
(
휇̂
)
≈
1(
휆̂
)4 Var
(
휆̂
)
=
1(
휆̂
)2
N
e
.
(6)Var(g(휃)) ≈
1
B
B∑
b=1
[
g
(
휃b
)
− g
(
휃̂
)]2
.
As this is a simulation-based method, it is not possible 
to derive analytic expressions for speciic models, as in the 
case of the delta method for the Weibull in Appendix 1 of 
the ESM. Both the delta method and the multivariate normal 
approximation are used in common statistical software; the 
former in STATA and the latter in the lexsurv package in 
R [11, 12].
2.3  Case Study: Datasets
We created four representative datasets to illustrate the 
impact of model choice on uncertainty in the estimated 
hazard and survival functions and mean survival. We gen-
erated all four datasets to have a sample size of 400, and 
mean survival of 0.9 years. We generated a dataset with a 
maximum follow-up of 1 year; any individuals who had not 
experienced an event by then were censored at 1 year. We 
applied no other censoring when creating the datasets. Each 
dataset may be viewed as describing outcomes for a single 
arm of a clinical trial, and was designed to represent difer-
ent common hazard patterns:
1. A constant hazard, based on 400 Monte Carlo samples 
from an exponential distribution.
2. A monotonically increasing hazard, based on 200 Monte 
Carlo samples from a Weibull distribution and 200 
Monte Carlo samples from a gamma distribution.
3. A monotonically decreasing hazard, based on 200 Monte 
Carlo samples from a Weibull distribution and 200 
Monte Carlo samples from a gamma distribution.
4. A unimodal hazard, based on 200 Monte Carlo samples 
from a log-logistic distribution and 200 Monte Carlo 
samples from a log-normal distribution.
For datasets 2–4, we used a mixture of distributions to 
avoid the dataset’s characteristics being driven by a single 
model.
Our intention was not to perform a simulation study. Sim-
ulation studies are useful tools for quantitatively evaluating 
the performance of statistical methods under certain sce-
narios [13]. In contrast, the aim of this study was to explore 
the qualitative behaviour of interval estimates arising from 
diferent survival models, and how these depend on model 
choice.
2.4  Case Study: Model Fitting and Analysis
We analysed the datasets assuming no knowledge of the 
distributions from which they were generated. We followed 
standard modelling practice by producing visual summaries 
of the data as part of an exploratory data analysis [14, 15]. 
We used two approaches to visualise the empirical hazard 
function: (1) smooth estimates of the empirical hazard over 
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time based on kernel density smoothing, and (2) unsmoothed 
estimates using piecewise time periods. We used the func-
tions muhaz and pehaz from the muhaz package [16] in R 
to generate the smoothed and unsmoothed versions, respec-
tively (the number of piecewise time periods was 25 based 
on default options). The advantage of examining both of 
these empirical estimates of the hazard function is that the 
smoothed estimates are expected to capture the underlying 
shape of the hazard function represented by the sample data, 
whilst the unsmoothed versions highlight the variability in 
the data.
We itted each of the models in Table 1 to each of the four 
datasets using the lexsurv package in R [12]. We then used 
each of the seven models to extrapolate hazard and survival 
functions for a lifetime. We used the multivariate normal 
method (the default approach in the lexsurv package) to 
generate 95% conidence intervals for the estimated hazard 
and survival functions. We used visual goodness of it to 
identify a candidate set of plausible extrapolation models. 
We calculated estimates of mean survival and the uncer-
tainty in these estimates for the candidate models, as these 
are an important summary measure in cost-efectiveness 
analyses.
We also performed a hypothetical cost-efectiveness anal-
ysis. This used the increasing hazards dataset (to relect the 
impact of ageing), and a two-state “well”, “dead” Markov 
model, with utility values of 1 and 0, respectively. We used 
hazard estimates from the candidate models to represent out-
comes for a control treatment, assuming it would cost £100 
every 2 weeks. We also assumed the intervention treatment 
would have a hazard ratio of 0.75 (applied directly to the 
hazard estimates) and cost an additional £100 every 2 weeks. 
We used a lifetime horizon of 10 years, with weekly cycles. 
The cost-efectiveness measure used was the incremental 
cost per quality-adjusted life-years gained. The probabilistic 
sensitivity analysis used 1000 samples.
3  Results
Figure 1 provides the characteristics of the four representa-
tive datasets, showing the Kaplan–Meier survival function 
for each dataset, and the smooth and piecewise estimators 
of the hazard function. Figure 1 also includes 95% coni-
dence intervals: for the survival functions these are based on 
Greenwood’s formula [6] and for the hazard estimates these 
are obtained via bootstrapping, as analytical formulae are 
not available. Figure 1 demonstrates that the characteristics 
of the datasets are as expected.
Figure 2 provides the seven model-based estimates of 
the hazard function with 95% conidence intervals. As the 
hazard function is bounded below by zero, conidence inter-
vals cannot fan out indeinitely. Instead, the logarithm of the 
hazard (which is not bounded) is displayed. Table 2 provides 
estimates for selected time periods. The exponential distri-
bution assumes a constant hazard at all time-points. Hence, 
it only provides a good visual it to the lat hazard dataset 
(see Fig. 2, irst column). We also observed a poor visual it 
for the Gompertz model for both the unimodal and decreas-
ing hazard datasets. For the decreasing hazard dataset, we 
also observed a poor it for the log-normal and log-logistic 
models.
Of the remaining candidate models, the width of coni-
dence intervals always decreased during the extrapolated 
phase for the log-logistic model. For all other models, there 
was an increase in the interval width, although this was 
generally slight for both the log-normal and the gamma 
distributions. For the lat hazard dataset, all seven models 
provide visually good its to the observed data. The expo-
nential, Weibull and Gamma models all extrapolate a (near) 
constant hazard, whilst the remaining models extrapolate a 
decreasing hazard. If external evidence or clinical opinion 
was available to inform the likely long-term behaviour of 
the hazard (constant or decreasing), this could be used to 
reduce the set of candidate models to at most three or four 
models. The choice between the remaining models may then 
be informed by the behaviour of the extrapolated hazard. For 
example, of the constant hazard extrapolations, estimates of 
uncertainty from the Weibull model are the closest to relect-
ing increasing uncertainty over time. If it is not possible to 
choose between constant and decreasing hazard models, then 
the Gompertz model may be preferred as the only model for 
which the uncertainty in extrapolations includes the possibil-
ity of both constant and decreasing hazards. Similar remarks 
hold for the other datasets. For example, given the variety 
in the plausible long-term extrapolations arising from the 
increasing hazards dataset, all of the models appear to under-
estimate extrapolation uncertainty, with the potential excep-
tion of the generalised gamma.
Figure 3 provides graphs of the estimated survival func-
tions over time and 95% conidence intervals on the logit 
scale to make them unbounded. It is easier to interpret the 
long-term behaviour of the models from the hazard plots 
(for example, from the survival plots, it is not clear which 
models are extrapolating a constant hazard for the lat hazard 
dataset). The visual lack of it of the models is also gener-
ally easier to interpret from the hazard plots. Note that when 
using the Gompertz distribution with a decreasing hazard, 
the extrapolated survival function will not reach zero (that is, 
it estimates that a proportion of individuals will never die).
Figure 4 displays estimates of lifetime mean survival for 
the candidate models. The results demonstrate that model 
choice inluences not only the point estimates of mean sur-
vival but also the uncertainty about these estimates. For 
the lat hazard dataset, the estimated standard error in the 
mean survival arising from the Gompertz model (0.36) is 
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Fig. 1  Visualisation of the 
Kaplan–Meier survival function 
estimate (with 95% coni-
dence interval) and empirical 
hazard estimates in the observed 
12-month period
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almost seven times larger than the estimate arising from the 
exponential model (0.05), and about three times larger than 
the estimates from the log-logistic and log-normal models 
(0.12 and 0.13, respectively), which provide similar point 
estimates of mean survival. For the increasing hazard data-
set, this diference in the estimate of uncertainty is reversed, 
with estimated standard errors from the log-logistic and log-
normal models (both 0.04) being almost twice those from 
the Gompertz model (0.02).
Appendix 2 of the ESM provides the summary cost-efec-
tiveness results. There was substantial variation in the esti-
mates of the mean incremental cost-efectiveness ratios from 
the six candidate models (from £18,500 to £29,600, both per 
quality-adjusted life-year) and their associated uncertainty, 
with the widths of the conidence intervals ranging over 
threefold, from £4400 to £14,500. Even when models pro-
vided near-identical point estimates (£29,500 and £29,600 
for the Weibull and generalised gamma, respectively), there 
remained large variation in the width of conidence intervals 
(£8400 and £14,500 respectively). For any given model, the 
expected value of information, which quantiies how much 
it would be worth spending on further research to reduce 
uncertainty in the cost-efectiveness results, was very small 
for a number of willingness-to-pay values. Appendix 2 of the 
ESM displays the results for a willingness to pay of £20,000 
per quality-adjusted life-year gained. At this level, the fund-
ing decision would be yes for the log-normal and log-logistic 
models, but no for the remaining models. Despite this, the 
expected value of information per person was £0 for the 
gamma, Weibull and Gompertz models, and between £0.09 
and £2.04 for the remaining models. This suggests that 
extrapolation uncertainty is not appropriately captured, as 
reducing this uncertainty could change the choice of survival 
model and hence the funding decision. Appendix 2 of the 
ESM provides further remarks.
Collectively, these results demonstrate that the efects of 
model choice on uncertainty in both the hazard functions and 
lifetime mean survival may be substantial, even for models 
that provide similar point estimates. Hence, analysts could 
under- or over-estimate the uncertainty in mean survival and 
hence measures of cost efectiveness unless they carefully 
consider model selection, in terms of both the model it dur-
ing the observed period and quantifying the uncertainty dur-
ing the extrapolation period.
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Fig. 2  Visualisation of the estimated hazard (and 95% conidence 
interval) in the observed and extrapolated periods for seven com-
monly used statistical time-to-event models studied in four hypotheti-
cal datasets. The dotted line shows the observed (smoothed) hazard 
and the vertical dashed line denotes the end of the observed time 
period
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4  Discussion
To our knowledge, this is the irst study to examine sys-
tematically the properties of seven diferent commonly used 
parametric survival models in terms of the uncertainty in 
estimates of extrapolated hazard and survival functions. We 
have provided exact analytical expressions for the expo-
nential model and described the use of the delta method 
and the multivariate normal method for obtaining approxi-
mate expressions. Using the four hypothetical datasets, we 
Table 2  Estimates of the hazard and its standard error for seven commonly used statistical time-to-event models studies in four hypothetical 
datasets
Gen. Gamma generalised gamma
Dataset and 
model
Time period (years)
0.5 1 1.5 2 2.5 3 3.5 4
Flat hazard
 Empirical 
(smooth)
1.09 (0.35) 0.93 (1.11)
 Exponential 1.16 (0.14) 1.16 (0.14) 1.16 (0.14) 1.16 (0.14) 1.16 (0.14) 1.16 (0.14) 1.16 (0.14) 1.16 (0.14)
 Weibull 1.14 (0.16) 1.11 (0.21) 1.09 (0.24) 1.08 (0.27) 1.07 (0.28) 1.06 (0.30) 1.05 (0.31) 1.05 (0.33)
 Gompertz 1.12 (0.14) 0.93 (0.27) 0.77 (0.38) 0.64 (0.47) 0.53 (0.53) 0.44 (0.58) 0.36 (0.61) 0.30 (0.64)
 Gamma 1.15 (0.16) 1.14 (0.19) 1.13 (0.21) 1.13 (0.22) 1.13 (0.22) 1.13 (0.23) 1.13 (0.23) 1.12 (0.23)
 Log-logistic 1.14 (0.17) 0.82 (0.13) 0.62 (0.09) 0.50 (0.07) 0.42 (0.06) 0.36 (0.05) 0.31 (0.04) 0.28 (0.04)
 Log-normal 1.03 (0.14) 0.73 (0.11) 0.58 (0.09) 0.49 (0.08) 0.42 (0.07) 0.37 (0.06) 0.34 (0.06) 0.31 (0.05)
 Gen. Gamma 1.12 (0.16) 0.94 (0.21) 0.83 (0.26) 0.75 (0.28) 0.69 (0.29) 0.64 (0.30) 0.61 (0.31) 0.57 (0.32)
Increasing hazard
 Empirical 
(smooth)
0.80 (0.27) 2.73 (1.95)
 Exponential 0.77 (0.09) 0.77 (0.09) 0.77 (0.09) 0.77 (0.09) 0.77 (0.09) 0.77 (0.09) 0.77 (0.09) 0.77 (0.09)
 Weibull 0.72 (0.12) 3.01 (0.58) 6.94 (2.25) 12.53 (5.33) 19.83 (9.98) 28.86 (16.44) 39.63 (25.37) 52.15 (36.08)
 Gompertz 0.58 (0.10) 4.02 (0.84) 28.02 
(12.87)
195.31 
(144.58)
1361.3 
(1,497.7)
9488 (14,576) 66,130 
(137,480)
460,913 
(1,274,871)
 Gamma 0.85 (0.13) 2.30 (0.38) 3.18 (0.57) 3.71 (0.71) 4.06 (0.80) 4.30 (0.85) 4.48 (0.89) 4.62 (0.92)
 Log-logistic 0.79 (0.13) 2.28 (0.34) 2.18 (0.30) 1.78 (0.22) 1.46 (0.17) 1.23 (0.14) 1.06 (0.12) 0.93 (0.10)
 Log-normal 0.96 (0.14) 1.86 (0.29) 2.01 (0.36) 1.96 (0.36) 1.86 (0.35) 1.76 (0.33) 1.66 (0.32) 1.57 (0.30)
 Gen. Gamma 0.72 (0.13) 3.07 (0.78) 7.51 (7.56) 14.4 (35.33) 23.97 (113.17) 36.43 (260.86) 51.93 (330.16) 70.63 (370.34)
Decreasing hazard
 Empirical 
(smooth)
1.05 (0.45) 1.18 (2.10)
 Exponential 1.72 (0.20) 1.72 (0.20) 1.72 (0.20) 1.72 (0.20) 1.72 (0.20) 1.72 (0.20) 1.72 (0.20) 1.72 (0.20)
 Weibull 1.01 (0.15) 0.73 (0.13) 0.60 (0.12) 0.53 (0.11) 0.47 (0.10) 0.43 (0.10) 0.4 (0.09) 0.38 (0.09)
 Gompertz 1.14 (0.19) 0.36 (0.15) 0.11 (0.08) 0.04 (0.04) 0.01 (0.02) < 0.01 (0.01) < 0.01 (< 0.01) < 0.01 (< 0.01)
 Gamma 1.08 (0.16) 0.89 (0.15) 0.81 (0.15) 0.77 (0.15) 0.74 (0.15) 0.72 (0.15) 0.7 (0.15) 0.69 (0.15)
 Log-logistic 0.82 (0.12) 0.48 (0.07) 0.34 (0.05) 0.27 (0.04) 0.22 (0.03) 0.19 (0.02) 0.16 (0.02) 0.15 (0.02)
 Log-normal 0.68 (0.09) 0.40 (0.06) 0.29 (0.04) 0.23 (0.03) 0.19 (0.03) 0.17 (0.02) 0.15 (0.02) 0.13 (0.02)
 Gen. Gamma 1.04 (0.17) 0.80 (0.20) 0.68 (0.23) 0.62 (0.25) 0.57 (0.27) 0.53 (0.29) 0.51 (0.30) 0.48 (0.31)
Unimodal hazard
 Empirical 
(smooth)
1.33 (0.42) 1.41 (1.41)
 Exponential 1.03 (0.12) 1.03 (0.12) 1.03 (0.12) 1.03 (0.12) 1.03 (0.12) 1.03 (0.12) 1.03 (0.12) 1.03 (0.12)
 Weibull 1.27 (0.16) 2.04 (0.38) 2.69 (0.67) 3.28 (0.96) 3.82 (1.28) 4.33 (1.60) 4.81 (1.92) 5.27 (2.24)
 Gompertz 1.09 (0.13) 2.26 (0.52) 4.69 (1.94) 9.73 (6.12) 20.17 (17.75) 41.81 (48.32) 86.68 (128.88) 179.69 (337.89)
 Gamma 1.36 (0.18) 1.88 (0.31) 2.13 (0.38) 2.28 (0.43) 2.38 (0.46) 2.45 (0.48) 2.50 (0.49) 2.54 (0.50)
 Log-logistic 1.47 (0.21) 1.52 (0.22) 1.23 (0.17) 0.99 (0.13) 0.82 (0.10) 0.70 (0.08) 0.60 (0.07) 0.53 (0.06)
 Log-normal 1.45 (0.19) 1.46 (0.23) 1.31 (0.22) 1.18 (0.20) 1.07 (0.19) 0.98 (0.17) 0.90 (0.16) 0.84 (0.15)
 Gen. Gamma 1.46 (0.19) 1.36 (0.31) 1.16 (0.39) 1.01 (0.43) 0.89 (0.44) 0.80 (0.44) 0.72 (0.44) 0.66 (0.43)
Model Choice and Extrapolation Uncertainty
illustrated how the choice of parametric survival model can 
strongly afect estimates of uncertainty about the hazard over 
the extrapolation period, and hence mean survival and cost-
efectiveness estimates. For each of the datasets considered, 
long-term uncertainty in the estimated hazard functions 
could be constant, increasing or decreasing, depending on 
the chosen model. We observed substantial diferences in the 
estimated magnitude of uncertainty for estimates of the haz-
ard function, lifetime mean survival and cost-efectiveness 
estimates.
Our indings are generalisable and applicable to datasets 
beyond the four used in this study. We have covered a range 
of commonly observed hazard patterns. Results will be qual-
itatively the same for other datasets that have similar hazard 
patterns because of the underlying mathematics that deines 
the estimated variance in the hazard for a given model. The 
magnitude of estimates of uncertainty will vary depending 
on the actual dataset used, but we would expect, for exam-
ple, that the uncertainty in the hazard of a itted generalised 
gamma model may fan out over time whereas that for a log-
logistic is likely to narrow over time.
There is existing guidance from the National Institute for 
Health and Care Excellence Decision Support Unit and in 
the literature on analysing and extrapolating survival data 
in cost-efectiveness analyses, which focus on commonly 
used parametric survival models [2, 17]. This guidance does 
not discuss the implications of survival model choice on 
estimates of uncertainty in model functions. A recent discus-
sion on methodological challenges noted that extrapolation 
involves methodological, structural and parameter uncer-
tainty, and that uncertainty increases as the extrapolated 
period increases [18]. Our study shows that survival model 
choice fundamentally inluences the estimates of uncertainty 
in hazard, mean survival and cost efectiveness.
There were some limitations of this work. First, we only 
examined seven commonly used parametric survival models 
[2]. There are other models that could be applied, as well 
as more lexible models such as spline-based models and 
fractional polynomials [19–22]. Further research into the 
impact on extrapolation uncertainty of using these mod-
els would be beneicial. As noted, six of the seven mod-
els that we considered are nested members of the general-
ised F family [23]. In theory, it may be possible to it the 
generalised F model and use signiicance testing to check 
if one of the nested models is to be preferred. There are 
two potential issues with this approach: irst, we were not 
always able to obtain model estimates from the generalised 
F, secondly, some of the nested models occur as parameters 
tend to ininity: model testing in this case is not straight-
forward [24]. Another limitation is that we did not consider 
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Fig. 3  Visualisation of the estimated survival (and 95% conidence 
interval) in the observed and extrapolated periods for seven com-
monly used statistical time-to-event models studied in four hypotheti-
cal datasets. The dotted line indicates the observed survival and the 
vertical dashed line denotes the end of the observed time period
 B. Kearns et al.
using a piecewise modelling approach, which allows for the 
data-generating mechanism to be diferent over time [25]. 
However, it would not automatically ensure (as might be 
preferred) that uncertainty increases as the extrapolated hori-
zon increases: this depends on the chosen survival model. 
Additionally, itting the extrapolating model to a subset of 
the sample data leads to a reduced sample size, and estimates 
of cost efectiveness can be sensitive to the choice of subset 
[26]. Further, we did not consider a dataset with multiple 
turning points in the hazard.
In practice, it is important that model choice involves 
input from clinical experts [2, 27]. This includes under-
standing both the underlying disease process (data-gener-
ating mechanism, or ‘true’ model) and how it evolves over 
time. The lack of data in the extrapolation period can create 
uncertainty in the appropriateness of using the itted model 
for extrapolation. For example, Davies and colleagues 
[28] extrapolated survival estimates for two interventions 
from Weibull models itted to 8 years of registry data. For 
one intervention, the model provided accurate predictions 
for the 8 years, but gave markedly inaccurate predictions 
when compared with a longer follow-up of the registry 
data to 16 years. This demonstrates that models that accu-
rately describe the observed data may not provide accurate 
extrapolations. Hence, it is important to relect any external 
evidence (including clinical knowledge) about the possibility 
that the data-generating mechanism will remain the same in 
the future. It is likely that there will be uncertainties in any 
external evidence, thus it is unlikely that their use will fully 
remove the uncertainties associated with extrapolation.
The results of this study have implications for a health 
economic analysis. Failure to quantify appropriately uncer-
tainty about inputs, including survival functions, over the 
observed and extrapolated periods may lead to incorrect 
estimates of population mean costs and beneits, which may 
afect reimbursement decisions. As well as afecting esti-
mates of mean cost efectiveness from a probabilistic sensi-
tivity analysis, the choice of survival model will also afect 
the estimated probability that interventions are cost efec-
tive. The results of this study also suggest that the failure to 
adequately account for extrapolation uncertainty can lead to 
value of information estimates that are too low.
In Box 1, we outline a set of recommendations for ana-
lysts and decision makers who are involved in generating 
or critiquing extrapolations. These recommendations aim to 
complement existing guidance (2, 12). We emphasise that 
considering estimates of uncertainty is important as a com-
ponent of the extrapolation process.
An important implication for further methodological 
research is to develop methods on how to incorporate the 
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notion that interval estimates of hazard functions should ‘fan 
out’ during the extrapolated period. A general approach to 
characterising extrapolation uncertainty may be required to 
relect that we have less knowledge about the data-generat-
ing mechanism in the future. A Bayesian approach would 
provide the ability to both incorporate external information 
and make probabilistic statements about the parameters of a 
survival model, taking into account the correlations between 
these parameters. This external information could include 
elicited beliefs from clinical experts about survival during 
the extrapolated period, or the plausibility of diferent mod-
els. Model discrepancy terms can be used to characterise 
uncertainty in model estimates [29]. An existing case study 
successfully demonstrated that it is possible to incorporate 
model discrepancy terms within the extrapolation period 
with the speciic aim of inducing a fanning out of uncer-
tainty in hazard estimates [19]. Further research into this 
approach should consider how to elicit both discrepancy 
terms and parameters in survival models [30]. Another 
advantage of the Bayesian approach is that it removes the 
need to use a multivariate normal approximation for the joint 
distribution of parameters in a survival model.
Finally, for this work, we generated representative (hypo-
thetical) datasets, but we did not conduct a simulation study. 
This was intentional, as the representative datasets were suf-
icient to highlight the impact of model choice on extrapola-
tion uncertainty. Further research could include a simulation 
study, to quantify the properties of survival models during 
the extrapolated period.
5  Conclusions
It is important for cost-efectiveness analyses to include 
realistic estimates of uncertainty about hazard functions 
and mean survival. This will improve both the accuracy of, 
and conidence in, reimbursement decisions. The choice of 
extrapolating model can have a large impact on estimates of 
uncertainty about hazard functions and lifetime mean sur-
vival. As such, consideration of the plausibility of estimates 
of uncertainty about hazard estimates in addition to point 
estimates of the hazard, particularly during the extrapolated 
period, should be informed by clinical knowledge as part 
of the model selection process. To support this, it is useful 
to visualise the observed and modelled hazard estimates as 
shown in the case study examples in this article. We provide 
seven new and speciic recommendations for analysts and 
decision makers to follow when considering the uncertainty 
in the extrapolated period and the impact of parametric sur-
vival model choice.
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Box 1  Recommendations for analysts and decision makers considering extrapolations from survival models
1. Analysts itting models to survival data for use in cost-efectiveness models should use input from clinical experts about the underlying 
disease process over the observed and extrapolated periods. Justiication should be provided regarding the implied hazard function, and the 
assumption that the chosen survival model will be valid for the extrapolation period. Analysts should generate and examine the empirical 
hazard function to aid in the choice of model based on the sample data.
2. The plausibility of extrapolated hazard estimates is a key part of survival model selection, complementing within-sample goodness of it. This 
assessment of plausibility should consider both point and interval (uncertainty) estimates. In general, extrapolations should be associated with 
uncertainty that increases over time, unless there are compelling arguments to the contrary.
3. In addition to considering the plausibility of extrapolated hazards, the impact on decision uncertainty should also be considered. This may 
be quantiied by the uncertainty in estimates of both lifetime mean survival and cost efectiveness. If follow-up data are almost complete, then 
diferences in estimates of uncertainty in the hazard function are less likely to be of importance.
4. Care should be taken when assuming that a single model for the hazard (and survival) function applies across all time points. Work to consider 
diferent models in diferent time periods should not only consider relecting the point estimates of the hazard functions, but also consider the 
implications for uncertainty in these estimates.
5. When reporting results of survival analyses in journal articles or to HTA/reimbursement authorities, a structured analysis of uncertainty 
should be provided including reporting and visualisation of the uncertainty about hazard functions (as in Fig. 2) and survival functions (as in 
Fig. 3) and in the mean survival (as in Fig. 4).
6. Analysts and decision makers should use scenario analyses to quantify the sensitivity of estimates of cost efectiveness to survival model 
choice. If structural uncertainty exists (more than one model structure could be appropriate), then this should be relected when calculating 
estimates of uncertainty in the base-case cost-efectiveness results. In the example provided here, this could suggest that the analyst uses the 
generalised gamma because the uncertainty in its estimates covers almost all of the other competing models (as detailed in Appendix 2 of the 
ESM).
7. If the use of commonly applied survival models does not adequately relect individuals’ notions of uncertainty about hazard functions for the 
extrapolated period, analysts should consider alternative innovative approaches (see the main text for examples).
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